{"id":"ak112-carboplatin-paxlitaxel","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AK112 functions as a dual checkpoint inhibitor by binding both PD-1 and LAG-3, removing inhibitory signals that suppress T cell activation and allowing enhanced anti-tumor immune responses. When combined with carboplatin (a platinum-based chemotherapy) and paclitaxel (a taxane that disrupts microtubule dynamics), the regimen provides both direct cytotoxic effects on cancer cells and immunological enhancement. This combination approach aims to improve response rates in solid tumors by leveraging both chemotherapy cytotoxicity and checkpoint-mediated immune activation.","oneSentence":"AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and LAG-3 on T cells to enhance anti-tumor immunity, combined with carboplatin and paclitaxel chemotherapy for direct tumor cell killing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:24.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (in combination with carboplatin and paclitaxel)"},{"name":"Other solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07103447","phase":"PHASE2","title":"Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC","status":"NOT_YET_RECRUITING","sponsor":"Shuangyue Liu","startDate":"2025-09-10","conditions":"Breast Cancer - Female","enrollment":54},{"nctId":"NCT05840016","phase":"PHASE3","title":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-08-17","conditions":"Advanced Squamous Non Small Cell Lung Cancer","enrollment":532}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AK112, Carboplatin, Paxlitaxel","genericName":"AK112, Carboplatin, Paxlitaxel","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and LAG-3 on T cells to enhance anti-tumor immunity, combined with carboplatin and paclitaxel chemotherapy for direct tumor cell killing. Used for Non-small cell lung cancer (in combination with carboplatin and paclitaxel), Other solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}